Pharmaceutical company Gedeon Richter UK has received full marketing and distribution rights for neuropsychiatry treatment Reagila (cariprazine). Reagila was acquired by Gedeon Richter UK from Recordati Pharmaceuticals, with Gedeon Richter picking up the rights for UK promotion of cariprazine. The drug is currently licensed in the UK… Read More
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending Ryeqo (relugolix 40mg, estradiol 1mg, and norethisterone acetate 0.5mg), for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. The decision makes the relugolix combination therapy… Read More
The first and only oral contraception containing a new, synthetic version of a naturally occurring oestrogen has been launched in the UK. Gedeon Richter’s Drovelis (14.2mg estetrol [E4] plus 3mg drospirenone [DRSP]) as a combined oral contraceptive is now available. The company cautions that any… Read More
